Boundless Bio (BOLD)

• Market cap: $27.5M
• 1 day: -2.38%
• 5 days: -10.87%
• 1 month: 0%
• 3 months: 7.89%
• 6 months: -19.61%
• Year to date: -54.95%
• 1 year: -62.95%
• 5 years: -91.37%
• 10 years: -91.37%
• Sector: Healthcare
• Industry: Biotechnology

About: Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Employees: 64